Navigation Links
Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
Date:2/2/2009

HAWTHORNE, N.Y., February 2, 2009 Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) on January 30, 2009 for Fampridine-SR, a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS). The Company expects that the NDA filing, if accepted, will be subject to standard review, which would provide a target for the FDA to complete its review within ten months from receipt of the submission.

"This NDA filing is a major milestone for Acorda and our Fampridine-SR development program," said Acorda Therapeutics President and CEO Ron Cohen, M.D. "Walking impairment is one of the most pervasive and alarming aspects of MS for patients, their families and their health care providers. There are no medicines currently indicated to improve walking ability in people with MS, and Fampridine-SR therefore may represent an important new approach to MS therapy. We are excited to have taken this major step toward potentially making Fampridine-SR available to help people with MS."

Approximately 400,000-500,000 people in the Unites States have MS, and recent studies indicate that between 64-85% of people with MS have walking disability1,2. Fully 70% of people with MS who have walking disability report it to be the most challenging aspect of their disease1.

The Fampridine-SR NDA submission is based on data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two Phase 3 trials that involved 540 people with MS and were conducted under Special Protocol Assessments (SPAs) from the FDA. The safety and efficacy profile of Fampridine-SR was consistent across Phase 2 and Phase 3 trials. Overall, the NDA filing included more that 50 clinical studies of Fampridine-SR. The total exposure to Fampridine-SR in MS studies filed as part of the NDA was over 1,20
'/>"/>

Contact: Jeff MacDonald
jmacdonald@acorda.com
914-347-4300
Ruder Finn Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. A novel target for therapeutics against Staph infection
2. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
3. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
4. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
5. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
6. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
7. Michael J. Fox Foundation PD Therapeutics Conference
8. Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration
9. ORNL supercomputer simulation wins prize for fastest-running science application
10. Track your fitness, environmental impact with new cell phone applications
11. New filtering technology has environmental, industrial applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... of Toronto-based researchers may be one step closer to a ... research and therapy. Induced pluripotent stem cells (iPSCs) can ... flexibly develop into many different types of cells. However, producing ... generation are largely unknown. But researchers from the University ...
... CHARGE syndrome* is a severe developmental disorder affecting multiple ... majority of patients carry a mutation in a gene ... broad spectrum of characteristic CHARGE symptoms has been a ... an important class of epigenetic regulators. DNA is wound ...
... that causes tuberculosis (TB) varies between patients of different ... tests to diagnose and monitor treatment for the disease, ... PLOS Pathogens . , The study, led by ... with the Medical Research Council,s National Institute for Medical ...
Cached Biology News:Toronto team ID proteins key in stem cell production 2Exercise rescues mutated neural stem cells 2Exercise rescues mutated neural stem cells 3Scientists discover ethnic differences in immune response to TB bacterium 2Scientists discover ethnic differences in immune response to TB bacterium 3
(Date:1/22/2015)... GEA Niro Soavi the leader in high ... PandaPLUS 2000, which is ideal for new applications for ... disruption . This compact laboratory homogenizer is the perfect ... food additives and ingredients as well as for the ...
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... January 22, 2015 Selexis SA, a ... Research Cell Banks (RCBs) used for drug discovery to ... Banks will include Next-Generation Sequencing (NGS) data ... de-risks biologic manufacturing by ensuring the integrity of the ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... Direct and indirect sales momentum gathers for the ... Feb. 28 /PRNewswire/ - Touch,Bionics, developer of the ... Prosthetic Supply) the leading U.S. O&P distributor today,announced ... distribution agreement for,the i-LIMB Hand in the United ...
... 28 PAREXEL International,Corporation (Nasdaq: PRXL ) ... James 29th Annual Institutional Investors Conference at the ... Senior Vice,President and Chief Financial Officer will be ... ET on Monday, March 3, 2008., A ...
... Microchip Biotechnologies, Inc.,(MBI) is collaborating with ... sample preparation system to generate template libraries,for ... project is to automate,the complex, multi-step upstream ... Pyrosequencing. "Using,MBI,s MOV technology to develop and ...
Cached Biology Technology:Touch Bionics signs U.S. distribution agreement with SPS 2PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference 2Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms 2
TP-1 (NDOG1)...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
Biology Products: